A new daily weight loss pill called orforglipron, manufactured by Eli Lilly, has demonstrated superior results to Wegovy in a clinical trial of over 1,500 adults with type 2 diabetes across five countries. After 12 months, participants taking orforglipron experienced 6-8% weight loss compared to 4-5% with oral semaglutide, along with bigger drops in average blood sugar levels. However, orforglipron caused more severe gastrointestinal side effects including vomiting and diarrhoea, leading up to 10% of trial participants to discontinue use, and the medication is still awaiting regulatory approval in Australia.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.